

Value Partners Health Care Fund

A Sub-Fund of Value Partners Ireland Fund ICAV

A UCITS-Compliant Fund ¹

NAV per unit: Class A USD Unhedged - USD18.23

Fund size : USD150.3 million



Morningstar Rating™
As at 31-12-2020


December 2020

- Value Partners Health Care Fund (the "Fund") primarily invests in equities and equity-related securities in healthcare companies on a worldwide basis.
- The investments of the Fund are concentrated in the health care sector which are subject to greater influences from government policies and regulations than those of other industries. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments.
- Investing in PRC market exposes the Fund to additional risks including currency repatriation risk, uncertainty of taxation policies and risk associated with StockConnects. The Fund may also expose to RMB currency and conversion risk.
- Investing in small/mid-capitalization securities may have lower liquidity and their prices are more volatile to adverse economic developments.
- The Fund may also invest in derivatives and debt securities that are below investment grade or unrated which can involve material risks, e.g. counterparty default risk, insolvency or liquidity risk, and may expose the Fund to significant losses.
- You should not make investment decision on the basis of this marketing material alone. Please read the prospectus for details and risk factors.

Investment objective

The Fund aims to achieve long-term capital growth by investing primarily in equities and equity related securities in healthcare companies, such as pharmaceuticals, biotechnology, healthcare services and medical technology and supplies, on a worldwide basis.

Performance since launch



Performance update

	Class A USD Unhedged	MSCI China All Shares Health Care 10/40 Index ²	CSI 300 Index ²
Year-to-date	+34.4%	+68.9%	+38.4%
One month	+5.1%	+15.4%	+5.8%
One year	+34.4%	+68.9%	+38.4%
Three years	+53.8%	+64.4%	+37.5%
Five years	+89.3%	+96.8%	+54.6%
Total return since launch	+82.3%	+92.6%	+35.4%
Annualized return since launch [^]	+11.0%	+12.1%	+5.4%

NAVs & codes

Classes	NAV	ISIN	Bloomberg
Class A USD Unhedged	18.23	IE00BSM8VZ90	VPHCUAU ID
Class A HKD Unhedged	17.82	IE00BSM8VQ00	VPHCUAH ID
Class A SGD Unhedged	12.97	IE00BSM8VV52	VPHCUAS ID

Top holdings

Name	Industry ³	%
Jiangsu Hengrui Medicine Co Ltd	Pharmaceuticals	9.6
Sino Biopharmaceutical Ltd	Pharmaceuticals	8.5
Yunnan Baiyao Group Co Ltd	Pharmaceuticals	6.0
Tianjin Zhongxin Pharmaceutical Group Corp Ltd	Pharmaceuticals	5.7
Hualan Biological Engineering Inc	Biotechnology	5.2
Jinxin Fertility Group Ltd	Health care services	4.4
Alibaba Health Information Technology Ltd	Health care technology	4.0
Changchun High and New Technology Industry (Group) Inc	Pharmaceuticals	3.7
Beijing Tiantan Biological Products Corp Ltd	Biotechnology	3.3
Fujian Green Pine Co Ltd	Commodity chemicals	3.1

These securities constitute 54% of the Fund.

Portfolio characteristics

As at 31 Dec 2020 ⁴

Price/earnings ratio	23.3 times		
Price/book ratio	2.9 times		
Portfolio yield	1.3%		
Annualized volatility (3 years) ⁵	Class A USD Unhedged	MSCI China All Shares Health Care 10/40 Index ²	CSI 300 Index ²
	16.7%	27.5%	22.7%

The Fund – Class A USD Unhedged: Monthly performance from 2 Apr 2015 to 31 Dec 2020

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Annual
2015	N/A	N/A	N/A	+2.5%	+3.6%	-6.2%	-5.3%	-7.5%	+0.3%	+7.5%	-1.7%	+4.1%	-3.7%
2016	-12.9%	-0.1%	+6.7%	-0.1%	-1.1%	+1.1%	+5.5%	+5.6%	+2.3%	-0.2%	+0.0%	-3.4%	+1.9%
2017	+2.3%	+1.6%	+2.0%	+1.3%	+0.8%	+2.7%	-1.6%	+0.7%	+1.5%	+5.9%	-0.7%	+2.7%	+20.8%
2018	+3.1%	-1.9%	+6.0%	-0.6%	+7.6%	-4.9%	-1.5%	-3.1%	-1.0%	-5.7%	+3.2%	-5.7%	-5.4%
2019	+2.9%	+8.1%	+5.9%	-1.1%	-5.9%	+1.4%	+1.1%	+3.7%	-3.2%	+6.3%	-3.8%	+5.0%	+21.0%
2020	-2.9%	+3.2%	-3.1%	+8.1%	+1.7%	+12.7%	+9.2%	+2.4%	-4.6%	-2.0%	+1.8%	+5.1%	+34.4%

[^] Annualized return is calculated from inception based on published NAV.

Geographical exposure by listing ⁶

China A-shares	49%
Hong Kong	32%
H-shares	4%
Red Chips	2%
Cash ⁷	13%

Sector exposure ^{3, 6}

Pharmaceuticals	49%
Biotechnology	16%
Health care services	5%
Health care equipment	4%
Health care technology	4%
Commodity chemicals	3%
Health care distributors	3%
Health care supplies	3%
Cash ⁷	13%

Fund facts

Manager:	Value Partners Hong Kong Limited
Base currency:	USD
Launch date:	Class A USD Unhedged/HKD Unhedged - 2 Apr 2015 Class Z RMB (CNH) Unhedged - 2 Apr 2015 Class A SGD Unhedged - 19 Jun 2018
Dealing frequency:	Daily, Cutoff time 11:59am Irish time
Legal status:	Authorized by the Central Bank of Ireland as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 ¹
Depository:	HSBC Continental Europe
Reporting:	www.valuepartners-group.com

Fee structure

	Class A	Class Z RMB (CNH)
Minimum subscription:	USD10,000 / HKD80,000 / SGD10,000	RMB10,000,000
Initial subscription fee:	Up to 5% of issue price	
Management fee:	1.5% p.a.	1.0% p.a.
Performance fee ⁸ :	15% of profit (high-on-high)	
Redemption fee:	Currently nil	

Source: HSBC Institutional Trust Services (Ireland) DAC and Bloomberg, data as at the last valuation date of the month as stated above, unless stated otherwise. Performance is calculated on NAV to NAV in base currency with dividend reinvested and net of fees. All indices are for reference only. Our portfolio disclosure policy can be obtained from the Investment Manager upon request to email fis@vp.com.hk.

* © Morningstar 2020. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. 1. Value Partners Health Care Fund is a sub-fund of Value Partners Ireland Fund ICAV (formerly Value Partners Ireland Fund plc), is an umbrella scheme with segregated liability between sub-funds authorised by the Central Bank of Ireland ("Central Bank") as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011. The ICAV is authorised and supervised by the Central Bank. Authorisation by the Central Bank shall not constitute a warranty as to the performance of the ICAV and the Central Bank shall not be liable for the performance or default of the ICAV. 2. With effect from 9 Oct 2020, the Fund uses MSCI China All Shares Health Care 10/40 Index and CSI 300 Index for performance comparison purpose. 3. Classification is based on Global Industry Classification Standard (GICS). 4. The profile is based on market consensus forecast as derived from FactSet and Bloomberg. Harmonic mean methodology is applied to calculate the forecast P/E ratio and P/B ratio. Portfolio yield is the weighted average of the total dividend yield of all securities in the portfolio. 5. Volatility is a measure of the theoretical risk in terms of standard deviation, based on monthly return over the past 3 years. 6. Exposure refers to net exposure (long exposure minus short exposure). Derivatives e.g. index futures are calculated based on P/L instead of notional exposure. 7. Cash includes receivables and payables (except cash for collaterals and margins). 8. Performance fee will only be charged if the NAV at the end of the financial year or upon realization of units exceeds the "high watermark", which is the all-time year-end high of the Fund's NAV. If in any one year, the Fund suffers a loss, no performance fee can be charged in subsequent years until the loss is recovered fully (the high-on-high principle).

Past Performance is not a guide to future performance and may not be repeated. The value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested. Exchange rate changes may cause the value of any overseas investments to rise or fall.

This document does not constitute an offer to anyone, or a solicitation by anyone, to subscribe for shares of Value Partners Ireland Fund ICAV. Nothing in this document should be construed as advice and is therefore not a recommendation to buy or sell shares.

Subscriptions for shares of the Fund can only be made on the basis of its latest Key Investor Information Document, prospectus and supplement together with the latest audited annual report (and subsequent unaudited semi-annual report, if published), copies of which can be obtained, free of charge, from www.valuepartners-group.com, your financial adviser or your regional contact. An investment in the Fund entails risks, which are fully described in the prospectus.

UK: This document is being distributed in UK by Value Partners (UK) Limited, which is authorised and regulated by the Financial Conduct Authority. This document is intended for distribution only to professional clients (as defined in the Markets in Financial Instruments Directive 2004/39/EC) and is not intended for distribution to retail investors.

Singapore: The Fund is registered as a restricted foreign scheme in Singapore and will only be distributed to (i) institutional investors and (ii) accredited investors and certain other persons in Singapore in accordance with section 304 and 305 of the Securities and Futures Act. Value Partners Asset Management Singapore Pte Ltd, Singapore Company Registration No. 200808225G. This material has not been reviewed by the Monetary Authority of Singapore.